Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations

Brown, Janet; Wood, Steven L.; Confavreux, C; Abe, Masahiro; Weilbaecher, K.; Hadji, Peyman; Johnson, Rachelle W.; Rhoades, Julie A.; Edwards, Claire; Croucher, Peter I.; Juàrez, Patricia; Badri, S. El; Arias-Pinilla, Gustavo A.; D’Oronzo, Stella; Guise, Theresa A.; Poznak, Catherine Van

doi:10.1016/j.jbo.2021.100375

Cited by 12 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Better targeted patient selection may become more apparent as new literature on predictive biomarkers (such as MAF status as identified in the updated AZURE analysis) becomes available [35] . It should be recognised that this survey was carried out before the COVID-19 pandemic, where, in the UK, there is evidence of a switch from IV BP use to oral BP use in order to reduce the need for hospital attendance [36] . Whether this pattern will revert post-pandemic or whether there will be a permanent shift towards oral adjuvant BPs remains to be seen.…”

Section: Discussionmentioning

confidence: 99%

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience

Porter

Theodoulou

Holen

et al. 2021

Journal of Bone Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience

Porter

Theodoulou

Holen

et al. 2021

Journal of Bone Oncology

View full text Add to dashboard Cite

“…Despite adherence with denosumab being generally high across the initiation, implementation, and persistence phases, there is scope for adherence to be improved. Some potential strategies are summarized in Table 3 [35][36][37][38]. Strategies to improve medication adherence may reduce avoidable hospitalizations and improve patient quality of life, with resulting cost savings [39,40].…”

Section: Discussionmentioning

confidence: 99%

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

Diel

Greil

Janssen

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Purpose To describe (non)adherence with denosumab among patients with solid tumors and bone metastases. Methods This retrospective, observational study pooled data from two completed prospective, multicenter cohort studies (X-TREME; Study 240) in adult patients with bone metastases from primary breast, prostate, lung, kidney, or other solid cancer types and administered denosumab 120 mg in routine clinical practice in Germany and Central and Eastern Europe. The studies were conducted between May 2012 and May 2017; pooled analysis was completed in August 2021. Medication adherence was described according to a three-component consensus taxonomy: initiation (first-ever administration ≤ 90 days from bone metastasis diagnosis), implementation (actual vs prescribed dosing; optimal implementation = regular/consistent dosing), and persistence (≤ 60-day gap between administrations at 3, 6, 9, and 12 months). Descriptive analyses were conducted for each cancer type. Results The analysis included 1748 patients with solid tumors and bone metastases. Adherence with denosumab was generally high across the initiation, implementation, and persistence phases. Most patients experienced timely initiation (from 64.4% [kidney cancer] to 81.2% [breast cancer]) and optimal implementation (from 62.4% [lung cancer] to 72.5% [breast cancer]). The proportion of patients who were persistent with treatment at 6 months ranged from 41.4% (lung cancer) to 77.8% (prostate cancer). Conclusions This study revealed variations by cancer type in the initiation, implementation, and persistence of denosumab in patients with solid tumors and bone metastases in routine clinical practice. Further cancer-specific studies are warranted to examine the determinants of (non)adherence with denosumab, and potential ways to improve medication adherence.

show abstract

“…For instance, in the midst of the COVID-19 outbreak, it was strongly recom-mended by leadership at DRCC/PRHC that all patients with painful, uncomplicated bony metastases were prescribed SFRT as a way to minimize patient volume and reduce risk of infections. During this pandemic, surveys indicate that 30% of patients with bone metastases were negatively affected by delays and lack of face-to-face patient communication [44] . No doubt, clinicians were required to change prescription patterns in order to adapt to these conditions.…”

Section: Future Directionmentioning

confidence: 99%

Exploring the utilization of single fraction radiation therapy for bone metastases at a community cancer centre

Niglas

Lavergne

2022

Journal of Medical Imaging and Radiation Sciences

View full text Add to dashboard Cite

Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations

Cited by 12 publications

References 26 publications

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

Exploring the utilization of single fraction radiation therapy for bone metastases at a community cancer centre

Contact Info

Product

Resources

About